Track topics on Twitter Track topics that are important to you
The use of androgen-deprivation therapy for treatment of non-metastatic, recurrent prostate cancer after local therapy is heavily debated, given the risks of treatment for the sake of controlling a disease that might not lead to life-threatening consequences. Findings from studies done almost 20 years ago had shown the survival benefits of early initiation of androgen-deprivation therapy compared with waiting for the appearance of symptoms or metastatic spread.1–3 Most of these landmark studies were done before the availability of testing for prostate-specific antigen (PSA), but nevertheless lead to widespread use of androgen-deprivation therapy in early, biochemically recurrent disease following local therapy.
Original Article: [Comment] Androgen deprivation in prostate cancer: first do no harmNEXT ARTICLE
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...